02:40:39 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SNY - SANOFI SPON ADR ECH REP 0.5 ORD SHS - http://www.sanofi-aventis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Q0.143.90·49.500.549.13-0.23-0.54,148.2201,43620,40648.84  49.47  48.1756.26  42.6319:12:39Jan 2515 min RT 2¢

Recent Trades - Last 10 of 20406
Time ETExPriceChangeVolume
19:12:39Q49.10-0.2696
18:17:03Q49.12-0.242
18:17:03Q49.13-0.235
16:00:04Q49.13-0.232,616
16:00:04Q49.13-0.23200
16:00:01Q49.13-0.23626
16:00:01Q49.13-0.23188
16:00:01Q49.13-0.2379
16:00:01Q49.13-0.234
16:00:01Q49.13-0.23108

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-01-25 14:29U:SNYNews ReleaseDupixent ‚ ® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
2024-01-23 01:00U:SNYNews ReleaseInhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
2023-11-30 08:30U:SNYNews ReleaseTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
2023-11-27 01:30U:SNYNews ReleaseDupixent ‚ ® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
2023-11-02 12:15U:SNYNews ReleaseSanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
2023-11-01 07:00U:SNYNews ReleaseSanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
2023-10-22 14:59U:SNYNews ReleaseDupixent ‚ ® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
2023-10-17 09:00U:SNYNews ReleaseSanofi Bridging the Gap between the Homeless and Society via Futsal
2023-10-10 08:00U:SNYNews ReleaseStagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
2023-10-04 01:07U:SNYNews ReleaseSanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
2023-09-26 01:29U:SNYNews ReleaseDupixent ‚ ® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
2023-09-14 06:00U:SNYNews ReleaseFirst Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
2023-09-13 08:15U:SNYNews ReleaseSanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
2023-07-25 08:00U:SNYNews ReleaseSanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
2023-07-20 08:00U:SNYNews ReleaseRecludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
2023-05-18 11:55U:SNYNews ReleaseSanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi